203 related articles for article (PubMed ID: 35931383)
1. Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.
Qiu H; Song E; Hu Y; Li T; Ku KC; Wang C; Cheung BMY; Cheong LY; Wang Q; Wu X; Hoo RLC; Wang Y; Xu A
Cell Mol Gastroenterol Hepatol; 2022; 14(5):1003-1023. PubMed ID: 35931383
[TBL] [Abstract][Full Text] [Related]
2. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
[TBL] [Abstract][Full Text] [Related]
3. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling.
Liu X; Zhang Y; Ma C; Lin J; Du J
Mol Biol Rep; 2022 Apr; 49(4):3113-3122. PubMed ID: 35107741
[TBL] [Abstract][Full Text] [Related]
4. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
Lee H; Ahn J; Shin SS; Yoon M
Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
[TBL] [Abstract][Full Text] [Related]
5. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
[TBL] [Abstract][Full Text] [Related]
7. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
9. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K; Yamaguchi K; Seko Y; Okishio S; Ishiba H; Tochiki N; Takahashi A; Kataoka S; Okuda K; Liu Y; Fujii H; Umemura A; Moriguchi M; Okanoue T; Itoh Y
Lab Invest; 2022 Mar; 102(3):281-289. PubMed ID: 34732847
[TBL] [Abstract][Full Text] [Related]
11. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk.
Liu Y; Dou X; Zhou WY; Ding M; Liu L; Du RQ; Guo L; Qian SW; Tang Y; Yang QQ; Pan DN; Li XY; Lu Y; Cheng JK; Tang QQ
Hepatology; 2021 Oct; 74(4):1864-1883. PubMed ID: 33934381
[TBL] [Abstract][Full Text] [Related]
14. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21.
Kim H; Mendez R; Zheng Z; Chang L; Cai J; Zhang R; Zhang K
Endocrinology; 2014 Mar; 155(3):769-82. PubMed ID: 24424044
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice.
Rusli F; Deelen J; Andriyani E; Boekschoten MV; Lute C; van den Akker EB; Müller M; Beekman M; Steegenga WT
Sci Rep; 2016 Jul; 6():30484. PubMed ID: 27470139
[TBL] [Abstract][Full Text] [Related]
16.
Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
19. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
[TBL] [Abstract][Full Text] [Related]
20. The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPARα/γ activity.
Chu Y; Gui S; Zheng Y; Zhao J; Zhao Y; Li Y; Chen X
Eur J Pharmacol; 2024 Apr; 969():176438. PubMed ID: 38402928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
